This article is an on-site version of our Coronavirus Business Update newsletter. Please share this with friends and colleagues who might find it valuable and let them know that, even if they are not subscribers to the Financial Times, they can read the newsletter — and all of the FT — free for 30 days. Welcome and please sign up here.
Get the latest worldwide picture with our vaccine tracker
For up-to-the-minute coronavirus updates, visit our live blog
As we report today, the global nature of coronavirus offers a rare worldwide opportunity for vaccine makers new and old. Or as one academic put it: “When you make a product essentially everyone in the world wants or needs, you are going to make a lot of money.”
The current leaders — Pfizer, Moderna, AstraZeneca and Johnson & Johnson — are set to be joined by Big Pharma rivals such as Sanofi and GlaxoSmithKline, but also by a wave of start-ups such as Novavax, CureVac and Valneva.
Although the new entrants face considerable hurdles such as coping with emerging variants — the World Health Organization yesterday ramped up warnings against the Delta strain sweeping Europe — and the possibility the public may prefer to go with existing jabs, the size of the market makes it worthwhile. Novavax is even forecast to overtake Moderna as the second-largest vaccine maker by revenue next year, with estimated sales of $17.9bn.
The need is pressing. As the FT Editorial Board points out, the priority for G7 leaders meeting today at what the UK is calling a “vaccines summit” must be to close the “dismal” gap that has opened up between rich and poor countries. Almost 45 per cent of the population of the G7 have had at least one jab, compared with about 2 per cent across Africa.
The vaccine divide goes beyond what the WHO deemed a “catastrophic moral failure”: it is also an economic folly, the FT says, threatening to hold back global recovery.
Although derided by pressure groups today as a “drop in the ocean”, G7 members will hope their pledge to donate 1bn vaccine doses to poorer countries, including 500m from the US, will help shake-off at least some of the criticism about rich countries hoarding supplies. They will also be hoping the move can help counter the “vaccine diplomacy” of China and Russia, which have been quick to sell their jabs to developing nations.
The UK economy grew a better than expected 2.3 per cent in April, thanks to retail spending and the reopening of schools, a pattern that should be repeated in May figures that will include the return of indoor hospitality. Separate data showed an improvement in trade as coronavirus and Brexit effects lessened.
US consumer prices rose 3.8 per cent in May compared with last year — the biggest jump in almost 13 years. Some argued the rise showed the economy was overheating but White House and Fed officials believe current increases are just a temporary phenomenon. The European Central Bank, meanwhile, raised its forecast for inflation even though it too emphasised increases would be transient. Catch up with our series: Inflation — a new era?
Thailand’s government is hoping that vaccinations can help reopen the country to tourism and repair some of the pandemic’s damage to the economy. But, as our Big Read explains, what some have labelled a botched rollout is an extremely politically sensitive issue: the vaccine is being made by a company owned by the country’s monarch and head of state.
US court documents showed Carnival boss Arnold Donald discussed the danger of coronavirus infections on the company’s ships at the start of last year but allowed cruises to go ahead. More than 2,000 Covid-19 cases and 80 deaths have been reported in connection with the Carnival cruises, according to the Miami Herald.
The FT revealed that Goldman Sachs’ US staff would have to disclose their vaccination status before next week’s planned return to the office, unlike rival Wall Street banks that have voluntary procedures. The US Equal Employment Opportunity Commission in December said employees could be barred from the workplace if they refused to be vaccinated, subject to religious and medical exemptions.
Big UK retailers including Frasers and Boots are caught up in debt wars with landlords over unpaid rent during the pandemic. Supermarket chain Wm Morrison, meanwhile, became the biggest UK victim so far of shareholder revolts over bosses’ pay at companies deemed to have done well during the pandemic.
Global stocks hit another all-time high as belief strengthened that a strong economic recovery was taking hold. The rate of increase, however, is slowing as investors await signals from the US Federal Reserve’s meeting next week on when it might start to pare back its emergency bond-buying programme.
The International Energy Agency said oil demand would pass pre-Covid levels by the end of 2022, although recovery would be uneven and could yet be dented by slow vaccine rollouts. Consumption dipped by 8.6m barrels a day in 2020 but is expected to improve by 5.4m b/d this year.
The bond market’s reaction to yesterday’s jump in US inflation was a distinct “meh”, writes Robert Armstrong in his Unhedged newsletter. He also leans towards the view that increases will be transitory but says we cannot relax just yet . . .
Sign up here to get Unhedged, our new briefing on markets and the business of finance, sent straight to your inbox every weekday
Millions of UK workers have seen their retirement plans wrecked by the pandemic. The FT Money team examines the challenges facing those in their fifties and early sixties, who have little time to recoup savings spent in the pandemic and may struggle to refinance pension pots.
GG comments on US and UK airline bosses call for transatlantic reopening:
After a one-year coronavirus delay, the Euro 2020 football extravaganza kicks off this evening. The tournament might not change the outcome of the pandemic, said one of the organisers, but it did at least have the potential to make people a little happier.
Sign up here for Scoreboard, our new must-read weekly briefing on the business of sport